Author Archives: Yedida Y Bogachkov PhD

FDA OKs Phase 2 Trial of Oral NE3107 in Easing Inflammation

The launch of a Phase 2 trial into the safety and early efficacy of oral NE3107 in treating Parkinson’s disease patients with motor fluctuations while on levodopa was approved by the U.S. Food and Drug Administration (FDA), BioVie, the therapy’s developer, announced. BioVie plans to initiate patient enrollment for the trial,…

Reach Further Campaign Hopes to Raise $30M for Research, Services

The Parkinson’s Foundation is launching a four-year, $30-million fundraising campaign to help advance Parkinson’s research and fund community services. The Reach Further campaign seeks to help accelerate research, increase patient access to healthcare, and enrich community services for those affected by Parkinson’s disease. “With the rate of…

Ask an expert survey graphic

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums